Takeda/ Millennium: The Price is Right
Executive Summary
Takeda and Millennium's recent out-sized tie-up reflects the different but real industry pressures from which both companies are suffering.Facing near-term patent exiprations of several key drugs, Takeda desperately needed to bulk up its R&D pipeline. Millennium, for its own part, was heavily dependent on the label expansion of its lead product, Velcade, as it struggled to maintain sustainable earnings growth and advance its early stage compounds through the clinic.
You may also be interested in...
Takeda Emerging Market Strategy Varies From Country To Country: An Interview With PharmAsia News
Takeda’s expansion into emerging markets using its Nycomed acquisition has positioned it well in Russia and Brazil and given Japan’s largest drug maker a small but solid base in China. But its head of international operations says he’s in no rush to expand into India, given the fluid and complex nature of that market.
Takeda Emerging Market Strategy Varies From Country To Country
Takeda’s expansion into emerging markets using its Nycomed acquisition have positioned it well in Russia and Brazil and given Japan’s largest drug maker a small but solid base in China, but its head of international operations says he’s in no rush to expand into India, given the fluid and complex nature of that market.
Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO
Shortly after the market closed on June 30, Biogen Idec and Exelixis confirmed leadership changes that will result in Exelixis's long-time CEO George Scangos taking the helm of the Big Biotech July 15